Tesamorelin Visceral Fat Reduction Research Mechanism
Tesamorelin Visceral Fat Reduction Research Mechanism A 2010 Phase III trial published in The Lancet found that HIV-associated lipodystrophy patients treated with tesamorelin for 26 weeks achieved a median 15.2% reducti…
Read article